JPRN-UMIN000016659CompletedPhase 1
Comparative study of the effects on L-dopa formulation absorption by the acid secretion inhibitor - Comparative study of the effects on L-dopa formulation absorption by the acid secretion inhibitor
tano National Hospital, National Hospital Organaization0 sites3 target enrollmentStarted: March 1, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 3
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.Subjects taking H2-receptor antagonists and Proton pump inhibitors 2.Subjects with allergy for L-dopa formulation,H2-receptor antagonists and Proton pump inhibitors 3.Subjects taking drugs that have interaction with L-dopa formulation,H2-receptor antagonists and Proton pump inhibitors 4.Subjects with glaucoma 5.Subjects with liver failure or renal dysfunction 6.Subjects with gastric ulcer,duodenal ulcer or with that history 7.Diabetic 8.Subjects with serious lung disease, serious cardiovascular disease,bronchial asthma or endocrine disorder 9.Subjects with psychiatric symptoms such as suicidal tendencies 10.Dialysis patient 11.Pregnant women or women who may possibly be pregnant 12.Subjects who are judged to be inadequate to participate in this trial at the blood sampling of provisional registration 13.Others, subjects who are judged to be inadequate to participate in this trial
Investigators
Similar Trials
Completed
Phase 3
Effects on the pharmacokinetics of L-DOPA formulation by Proton pump inhibitors in patients with Parkinson's diseaseParkinson's diseases diseaseJPRN-UMIN000022529tano National Hospital, National Hospital Organization8
Active, not recruiting
Not Applicable
Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP)Hereditary spastic paraplegias (HSP) are a rare neurodegenerative group of disorders characterised by slowly progressive symmetric spastic paraparesis, distal pallhypaesthesia of the lower limbs, and urinary dysfunction. Based on clinical hallmarks, noncomplicated HSP and complicated forms are known. Clinically, HSP forms are similar but genetically even more heterogeneous.EUCTR2004-004509-11-DEniversity hospital of the University of Ulm
Completed
Phase 1
Pharmacokinetic study of levodopa coadministration of lactoferrin in healthy volunteersJPRN-UMIN000026787Ehime university8
Completed
Phase 2
Comparison of the effects of dopamine and dobutamine on children with hypotension admitted to the intensive care unit.HypotensionIRCT20210116050051N1Arak University of Medical Sciences81
Completed
Phase 2
The effect of levodopa on strokeIschemic stroke.Middle cerebral artery syndrome (I66.0+)IRCT2014042017360N1Ahvaz jundishapour university of medical science114